Temps are falling and so is investor cash as BioSpace reviewed which biotech companies are scooping up the dollars.
When AstraZeneca presented positive updated results from the Phase III ASCEND study of CALQUENCE (acalabrutinib), it marked an important milestone for the company as the jewel in the crown of what management hopes will become a significant hematology portfolio. That study was significant for patients, too, because it represented a landmark 36 months of follow-up in chronic lymphocytic leukemia (CLL), which is considered an incurable disease.
Traditional management tools have proven to be ineffective at managing costs for oncology drugs, leading to a hands-off management approach in the United States. But a recent survey from Two Labs – including 25 Pharmacy Directors and Medical Directors at US insurance companies representing 112.5 million covered lives – shows that the situation might be changing. The survey aimed to gather insight about what the industry looks like with increased levels of care management by covering traditional management tools, oncology-specific tools, systemic management tools and shifting risk, value frameworks, and pathways of care.
Positive high-level results from the ELEVATE-RR Phase III trial showed AstraZeneca’s Calquence (acalabrutinib) met the primary endpoint demonstrating non-inferior progression-free survival for adults with previously treated, high-risk chronic lymphocytic leukemia (CLL) compared to ibrutinib.
The American Society of Hematology (ASH) Annual Meeting & Exposition began December 5 with numerous presentations, abstracts and posters.
Roche Group member Genentech announced that new data from the pivotal Phase III MURANO and CLL14 studies support the efficacy of fixed-duration, chemotherapy-free Venclexta (venetoclax)-based combinations in certain people with chronic lymphocytic leukemia (CLL) and provide more evidence on the potential value of minimal residual disease.
Verastem signed a definitive deal to sell the company’s global commercial and development rights for Copiktra (duvelisib) to Secura Bio.
The U.S. Food and Drug Administration approved Imbruvica (ibrutinib) in combination with Rituxan (rituximab) for chronic lymphocytic leukemia or small lymphocytic lymphoma patients who are new to therapy.
Hundreds of studies and results were presented at the 61st American Society of Hematology (ASH) Annual Meeting.
Bristol-Myers Squibb announced positive results for the CAR-T therapy lisocabtagene maraleucel (liso-cel) in three studies at the American Society of Hematology Annual Meeting.
